According to tests carried out on 17 thousand volunteers, the effectiveness of the vaccine reached 79% and could increase to 89% in severe cases of the disease
one of the main biomedical research institutions in Brazil, has started production of a new counter to , with the aim of delivering 1 million doses in 2025. The ambitious goal is to reach the production of 100 million doses by 2027. vaccine, called Butantã DV, is currently awaiting approval from (Anvisa), which has not yet established a deadline for finalizing the evaluation of the documentation submitted in December last year.
Butantã DV was tested on 17,000 volunteers, demonstrating an efficacy of 79%, which can increase to 89% in severe cases of the disease. If approved, the vaccine will be administered in a single dose and is tetravalent, offering protection against the four types of dengue virus. The age range for applying the vaccine covers people from 2 to 60 years old, which represents a significant advance in the fight against dengue in Brazil, especially considering the alarming increase in cases, which exceeded 6 million last year.
Currently, vaccination against dengue in Brazil is carried out with an immunizer of Japanese origin, whose availability is quite limited. The expectation is that local production will not only increase the availability of the vaccine, but also reduce costs and facilitate distribution logistics across the country.
Published by Luisa Cardoso
